Investor News / RNS

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication with Astellas Pharma Inc. (“Astellas”) of an original peer reviewed article “A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination with Pembrolizumab” in the journal “CPT: Pharmacometrics & Systems...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce that the Innovate UK Funded project called PREDICT-ONC has now received both regulatory and ethical approval.   The Company’s personalised dosing software has been developed primarily with grant funding from UK bodies, including £68,000 from Innovate UK (March 2018), £150,000...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.   The project will involve the application of Pharmacokinetic-Pharmacodynamic (PK/PD) modelling to inform the Target Candidate Profile (“TCP”) of a key asset in Numab Therapeutic’ pipeline. Delivery of the project...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce it has been awarded a new contract with a long-standing, globally recognised pharmaceutical client. The project, valued at £157k, will leverage Physiomics’ expertise in Pharmacokinetic-Pharmacodynamic (“PKPD”) modelling to inform critical pre-clinical and clinical dosing and scheduling decisions for a...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Dr Peter Sargent, Chief Executive Officer and Director of the Company, has acquired, via market purchases, 459,090 new ordinary shares of 0.4p in the Company (“Ordinary Shares”) at a price of 0.66p per Ordinary Share.   Click here to read in full...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Mark Davies, as Head of Quantitative Pharmacology and Data Science.   Dr Mark Davies brings over 20 years’ experience in drug development, both from the perspective of...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a new contract by an existing client Cancer Research UK. The project involves the development of Pharmacokinetic Pharmacodynamic (PK/PD)* model to simulate the exposure-response relationship for a novel oncology therapy to guide starting...

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to provide notice of the Company’s Annual General Meeting (“AGM”).   The AGM will be held at 10.30 a.m. on 19 November 2024 at the Company’s registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Shareholders will shortly be sent either...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its End of Year results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/       Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive...